| 发明名称 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | ||
| 摘要 | The present invention relates to compounds of formula (I);wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT) and non-small cell lung cancer (NSCLC). | ||
| 申请公布号 | US8895744(B2) | 申请公布日期 | 2014.11.25 |
| 申请号 | US200913062665 | 申请日期 | 2009.08.27 |
| 申请人 | Universita' Degli Studi di Milano-Bicocca;Universite' de Geneve;Universite' Claude Bernard de Lyon 1 | 发明人 | Gambacorti Passerini Carlo;Mologni Luca;Scapozza Leonardo;Ahmed Shaheen;Goekjian Peter G.;Gueyrard David;Popowycz Florence;Joseph Benoit;Schneider Cedric;Garcia Pierre |
| 分类号 | A61K31/44;C07D221/22;C07D471/04 | 主分类号 | A61K31/44 |
| 代理机构 | Arent Fox LLP | 代理人 | Arent Fox LLP |
| 主权项 | 1. A compound of formula (I): wherein when R1 is nil or when R1 is attached in the 2 position of the α-carboline ring, R1 is selected from the group consisting of: when R1 is attached in the 3 position of the α-carboline ring, R1 is selected from the group consisting of: when R1 is attached in the 4 position of the α-carboline ring, R1 is selected from the group consisting of: wherein R2 is selected from the group consisting of: wherein R3 is selected from the group consisting of hydrogen, methyl, ethoxymethyl, tert-butyloxycarbonyl and benzenesulfonyl; wherein a dashed line across a bond indicates the point of attachment of the group to the α-carboline ring, or a stereoisomer, enantiomer, diastereoisomer or a pharmaceutically acceptable salt thereof. | ||
| 地址 | Milan IT | ||